The effect of alirocumab, a PCSK9 inhibitor, on the plaque volume and characteristics were evaluated in the PACMAN-AMI (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction) randomized trial (15). This evidence concerns the gene PCSK9 and myocardial infarction.